Objective: To evaluate the efficacy and toxicity of stereotactic body radiation therapy (SBRT) for oligometastatic pulmonary tumors from cervical cancer.
INTRODUCTION
Cervical cancer is one of the most common cancers in China. It was estimated that there were 98.9 thousand new cervical cancer cases and 30.5 thousands deaths in 2015. 1 With the changes of treatment pattern and development of treatment technique, the local control (LC) of cervical cancer improved significantly. After definitive treatment, there was more distant failure than local failure. 2, 3 Pulmonary metastasis is one of the most common sites of distant failure. It was reported that the incidences of pulmonary metastasis were 1.8-2.1%. 4, 5 For pulmonary metastases from cervical cancer after initial treatment (radical surgery or definitive radiotherapy), pulmonary resection is an efficacy approach, with a 5-year survival of more than 30%. 6, 7 However, only patients with few metastatic lesions limited to the lungs and good general condition could receive pulmonary resection and only a small number of patients meets these criteria. Most patients with pulmonary metastases from cervical cancer were treated with chemotherapy or radiotherapy. As a palliative treatment, the survival after single chemotherapy was poor. Panek et al. reported that, after platinum-5-fluorouracil chemotherapy, only 12% of patients with pulmonary metastases from cervical cancer achieved complete response (CR). The overall survival (OS) and progression-free survival (PFS) at 3 years were 17.6% and 14.3%, respectively. 8 Patients with oligopulmonary metastases from cervical cancer still have opportunity to have long-term survival. Therefore, just giving these patients single chemotherapy is unreasonable.
In the past, radiotherapy was often used as a palliative approach for pulmonary metastases. As a new technique, stereotactic body radiation therapy (SBRT) could accurately deliver high dose to the lesions in few fractions. In pulmonary metastasis from rectum and soft tissue sarcoma, SBRT had been proved to be a safe and effective approach [9] [10] [11] and became an important alternative to resection.
For the use of SBRT in pulmonary metastases from cervical cancer, researches are limited. In this article, we retrospectively analyzed the efficacy and toxicity of SBRT for patients with pulmonary metastases from cervical cancer after definitive treatment in our institute.
MATERIALS AND METHODS

Patients
We retrospectively analyzed patients with pulmonary metastases The patients, tumor and treatment characteristics were shown in At the time of SBRT, the median age was 47 years old (range, 26-67). The time interval from CR of primary tumor to the appearance of lung metastases was disease-free interval (DFI). The median DFI was 10.7 months.
There were 29 lesions for these 19 patients in total. The mean number of lung metastases was 1.5 (range, [1] [2] [3] [4] Table 1 .
Treatment
Outcome evaluation and statistical analysis
Response Evaluation Criteria in Solid Tumors criteria was used to assess the treatment efficacy. Treatment-related adverse effects were 
RESULTS
The median follow-up was 9.5 months (range, 3.0-62.4). The median follow-up for patients alive was 18.9 months (range, 3.6-62.4 Yamamoto et al. reported 29 patients with pulmonary metastases from cervical cancer, which were detected after a disease-free period after initial treatment and were resected with the intention to cure. A solitary lesion was found in 17 patients, 2 lesions were found in 6 patients, 3 lesions in 3 patients and 4 lesions in 3 patients. The 5-year DFS rate was 32.9% for all patients. For 23 patients with one to two pulmonary lesions, the 5-year DFS was 42.2%. 6 Anraku et al. treated 76 patients with pulmonary metastases from cervical cancer with surgical resection, the 5-year OS was 45.7%. 7 For patients with pulmonary metastases from cervical cancer after radical treatment, surgical resection is an efficacy approach. The 5-year survival was higher than 30%.
For patients with pulmonary metastases, SBRT was an effective treatment option. The 2 or 3-year LC rate was higher than 70%. [9] [10] [11] In the pooled analysis of Germen working group, 700 patients with medically inoperable lung metastases in 20 centers were treated with SBRT.
The most common primary tumors included non-small cell lung cancer (NSCLC, n = 210), colorectal cancer (n = 153), sarcoma (n = 51) and so on. Solitary pulmonary metastases were found in 246 patients (42.4%).
The median diameter of the lesions was 2.2 cm (range 0.4-9.4 cm).
The median single fraction dose of PTV was 12.5 Gy (range 3-33 Gy) and the median number of SBRT fractions was 3 (range, 1-13 In our study, the 2-year OS, PFS and LC rates were 76.8%, 37.2% and 75.6%, respectively. To our knowledge, this was the first study on SBRT for pulmonary metastases from cervical cancer. A dose of 50 Gy in 10 fractions was delivered to PTV and 70 Gy in 10 fractions was prescribed to the GTV. The other 31 patients were treated by surgical resection. For SRS group and surgical group, the 2-year OS rates were 40.7% and 48.3% (P > 0.05), the 2-year PFS rates were 33.3% and 38.7% (P > 0.05). 13 In this study, the 2-year PFS rate was 37.2%. Six of 19 patients (31.6%) appeared to be disease free for more than 20 months. The outcome was close to the data of pulmonary resection. 6, 7 This indicated that, for operable patients, SBRT
was also a potential alternative to resection for oligometastatic pulmonary tumors from cervical cancer. Considering the small number of patients and short follow-up period, we need more studies on this. in a median number of three fractions (range 1-13). 9 The radiation sensitivity of lung metastases varies with different primary tumors.
The radiation sensitivity of cervical cancer was comparatively higher than sarcoma, colorectal cancer, renal cell carcinoma and NSCLC et al.
In this study, the most common dose fractionations were 64 Gy in 8 fractions (8 lesions), 56 Gy in 7 fractions (7 lesions). The median BED was 100.8 Gy (56-120 Gy). With these dose fractionations, SBRT achieved excellent LC and promising OS. This may provide an acceptable dose fractionation option for pulmonary metastases from cervical cancer.
It was reported that the incidence rates of grade 2 or greater radiation pneumonitis were 0-6.5% for patients with pulmonary metastases when they treated with SBRT. [9] [10] [11] 15, 16 In this study, only 1 (5.3%) patients had grade 2 radiation pneumonitis, which was similar with previous reports.
There were some limitations in this study. The number of patients with pulmonary metastases from cervical cancer was small and the follow-up period was short. As pulmonary metastases from cervical cancer are comparatively rare, 4 multi-institute studies are needed to collect more patients in the future.
SBRT was an efficacy and safe approach for patents with oligometastatic pulmonary tumor from cervical cancer. SBRT should be considered as a potential alternative to resection for these patients.
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